Answers are grounded in this paper and cite their sources.
Randomized trial pooled analysis reveals no neuropsychiatric safety concerns with liraglutide 3.0 mg for weight management, suggesting minimal risk of depression or suicidal behavior.
Results of this exploratory pooled analysis provide no cause for concern regarding the neuropsychiatric safety of treatment with liraglutide 3.0 mg in patients similar to those included in the examined trials. Although there was a small numerical imbalance in suicidal ideation with liraglutide through adverse event reporting, no between-treatment imbalances in suicidal ideation/behaviour or depression were noted through prospective questionnaire assessments.
No takes yet. Share an insight, caveat, or question.
O’Neil et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: